Serious Complications Associated with Stereotactic Ablative Radiotherapy and Strategies to Mitigate the Risk

Clinical Oncology

Volumn 25, Issue 6, 2013, Pages 378-387

  Lo, S S ^a   Sahgal, A ^b   Chang, E L ^c   Mayr, N A ^d   Teh, B S ^e   Huang, Z ^f   Schefter, T E ^g   Yao, M ^a   Machtay, M ^a   Slotman, B J ^h   Timmerman, R D ⁱ  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e HOUSTON METHODIST HOSPITAL   (United States)

^f EAST CAROLINA UNIVERSITY   (United States)

^g UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^h VU UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Risk; Serious complications; Stereotactic ablative radiotherapy

Indexed keywords

ARTICLE; BODY MASS; BRACHIAL PLEXOPATHY; CANCER RADIOTHERAPY; CHILD PUGH SCORE; COMPRESSION FRACTURE; DIABETES MELLITUS; DOSIMETRY; DUODENUM INJURY; ESOPHAGUS INJURY; HIGH RISK PATIENT; HUMAN; KIDNEY DYSFUNCTION; LIVER CELL CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; ORGANS AT RISK; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RADIATION INJURY; RADIATION PNEUMONIA; RESPIRATORY TRACT DISEASE; RISK MANAGEMENT; SKIN TOXICITY; SPINAL CORD DISEASE; SPINE FRACTURE; STEREOTACTIC BODY RADIATION THERAPY; STOMACH INJURY; THORAX PAIN; THORAX WALL DEFECT;

DOSE FRACTIONATION; HUMANS; NEOPLASMS; RADIOSURGERY; RISK FACTORS;

EID: 84877147428     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2013.01.003     Document Type: Article

References (68)

1. Lo S.S., Fakiris A.J., Chang E.L., et al. Stereotactic body radiation therapy: a novel treatment modality. Nat Rev Clin Oncol 2010, 7:44-54.
2. Sahgal A., Ma L., Gibbs I., et al. Spinal cord tolerance for stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2010, 77:548-553.
3. Sahgal A., Ma L., Weinberg V., et al. Reirradiation human spinal cord tolerance for stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2012, 82:107-116.
4. Barriger R.B., Forquer J.A., Brabham J.G., et al. A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2012, 82:457-462.
5. Andolino D.L., Forquer J.A., Henderson M.A., et al. Chest wall toxicity after stereotactic body radiotherapy for malignant lesions of the lung and liver. Int J Radiat Oncol Biol Phys 2011, 80:692-697.
6. Forquer J.A., Fakiris A.J., Timmerman R.D., et al. Brachial plexopathy from stereotactic body radiotherapy in early-stage NSCLC: dose-limiting toxicity in apical tumor sites. Radiother Oncol 2009, 93:408-413.
7. Hoppe B.S., Laser B., Kowalski A.V., et al. Acute skin toxicity following stereotactic body radiation therapy for stage I non-small-cell lung cancer: who's at risk?. Int J Radiat Oncol Biol Phys 2008, 72:1283-1286.
8. Andolino D.L., Johnson C.S., Maluccio M., et al. Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2011, 81:e447-453.
9. Timmerman R., McGarry R., Yiannoutsos C., et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006, 24:4833-4839.
10. Yamashita H., Nakagawa K., Nakamura N., et al. Exceptionally high incidence of symptomatic grade 2-5 radiation pneumonitis after stereotactic radiation therapy for lung tumors. Radiat Oncol 2007, 2:21.
11. Timmerman R., Paulus R., Galvin J., et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010, 303:1070-1076.
12. Nagata Y., Takayama K., Matsuo Y., et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys 2005, 63:1427-1431.
13. Baumann P., Nyman J., Hoyer M., et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol 2009, 27:3290-3296.
14. Ricardi U., Filippi A.R., Guarneri A., et al. Stereotactic body radiation therapy for early stage non-small cell lung cancer: results of a prospective trial. Lung Cancer 2010, 68:72-77.
15. Yamashita H., Kobayashi-Shibata S., Terahara A., et al. Prescreening based on the presence of CT-scan abnormalities and biomarkers (KL-6 and SP-D) may reduce severe radiation pneumonitis after stereotactic radiotherapy. Radiat Oncol 2010, 5:32.
16. Ong C.L., Palma D., Verbakel W.F., Slotman B.J., Senan S. Treatment of large stage I-II lung tumors using stereotactic body radiotherapy (SBRT): planning considerations and early toxicity. Radiother Oncol 2010, 97:431-436.
17. Guckenberger M., Baier K., Polat B., et al. Dose-response relationship for radiation-induced pneumonitis after pulmonary stereotactic body radiotherapy. Radiother Oncol 2010, 97:65-70.
18. Dunlap N.E., Cai J., Biedermann G.B., et al. Chest wall volume receiving >30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2010, 76:796-801.
19. Stephans K.L., Djemil T., Tendulkar R.D., Robinson C.G., Reddy C.A., Videtic G.M. Prediction of chest wall toxicity from lung stereotactic body radiotherapy (SBRT). Int J Radiat Oncol Biol Phys 2012, 82:974-980.
20. Pettersson N., Nyman J., Johansson K.A. Radiation-induced rib fractures after hypofractionated stereotactic body radiation therapy of non-small cell lung cancer: a dose- and volume-response analysis. Radiother Oncol 2009, 91:360-368.
21. Welsh J., Thomas J., Shah D., et al. Obesity increases the risk of chest wall pain from thoracic stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2011, 81:91-96.
22. Mutter R.W., Liu F., Abreu A., Yorke E., Jackson A., Rosenzweig K.E. Dose-volume parameters predict for the development of chest wall pain after stereotactic body radiation for lung cancer. Int J Radiat Oncol Biol Phys 2012, 82:1783-1790.
23. Voroney J.P., Hope A., Dahele M.R., et al. Chest wall pain and rib fracture after stereotactic radiotherapy for peripheral non-small cell lung cancer. J Thorac Oncol 2009, 4:1035-1037.
24. McGarry R.C., Papiez L., Williams M., Whitford T., Timmerman R.D. Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: phase I study. Int J Radiat Oncol Biol Phys 2005, 63:1010-1015.
25. Joyner M., Salter B.J., Papanikolaou N., Fuss M. Stereotactic body radiation therapy for centrally located lung lesions. Acta Oncol 2006, 45:802-807.
26. Song S.Y., Choi W., Shin S.S., et al. Fractionated stereotactic body radiation therapy for medically inoperable stage I lung cancer adjacent to central large bronchus. Lung Cancer 2009, 66:89-93.
27. Corradetti M.N., Haas A.R., Rengan R. Central-airway necrosis after stereotactic body-radiation therapy. N Engl J Med 2012, 366:2327-2329.
28. Gomez D.R., Hunt M.A., Jackson A., et al. Low rate of thoracic toxicity in palliative paraspinal single-fraction stereotactic body radiation therapy. Radiother Oncol 2009, 93:414-418.
29. Cox B.W., Jackson A., Hunt M., Bilsky M., Yamada Y. Esophageal toxicity from high-dose, single-fraction paraspinal stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 2012, 83:e661-667.
30. Abelson J.A., Murphy J.D., Loo B.W., et al. Esophageal tolerance to high-dose stereotactic ablative radiotherapy. Dis Esophagus 2012, 25:623-629.
31. Rusthoven K.E., Kavanagh B.D., Cardenes H., et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 2009, 27:1572-1578.
32. Lee M.T., Kim J.J., Dinniwell R., et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol 2009, 27:1585-1591.
33. Tse R.V., Hawkins M., Lockwood G., et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2008, 26:657-664.
34. Herfarth K.K., Debus J., Lohr F., et al. Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol 2001, 19:164-170.
35. Hoyer M., Roed H., Traberg Hansen A., et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol 2006, 45:823-830.
36. Sawrie S.M., Fiveash J.B., Caudell J.J. Stereotactic body radiation therapy for liver metastases and primary hepatocellular carcinoma: normal tissue tolerances and toxicity. Cancer Control 2010, 17:111-119.
37. Cardenes H.R., Price T.R., Perkins S.M., et al. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol 2010, 12:218-225.
38. Hoyer M., Roed H., Sengelov L., et al. Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiother Oncol 2005, 76:48-53.
39. Schellenberg D., Goodman K.A., Lee F., et al. Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2008, 72:678-686.
40. Murphy J.D., Christman-Skieller C., Kim J., Dieterich S., Chang D.T., Koong A.C. A dosimetric model of duodenal toxicity after stereotactic body radiotherapy for pancreatic cancer. Int J Radiat Oncol Biol Phys 2010, 78:1420-1426.
41. Svedman C., Karlsson K., Rutkowska E., et al. Stereotactic body radiotherapy of primary and metastatic renal lesions for patients with only one functioning kidney. Acta Oncol 2008, 47:1578-1583.
42. Sahgal A., Larson D.A., Chang E.L. Stereotactic body radiosurgery for spinal metastases: a critical review. Int J Radiat Oncol Biol Phys 2008, 71:652-665.
43. Sahgal A., Weinberg V., Ma L., et al. Probabilities of radiation myelopathy specific to stereotactic body radiation therapy to guide safe practice. Int J Radiat Oncol Biol Phys 2013, 85:341-347.
44. Rose P.S., Laufer I., Boland P.J., et al. Risk of fracture after single fraction image-guided intensity-modulated radiation therapy to spinal metastases. J Clin Oncol 2009, 27:5075-5079.
45. Boehling N.S., Grosshans D.R., Allen P.K., et al. Vertebral compression fracture risk after stereotactic body radiotherapy for spinal metastases. J Neurosurg Spine 2012, 16:379-386.
46. Cunha M.V., Al-Omair A., Atenafu E.G., et al. Vertebral compression fracture (VCF) after spine stereotactic body radiation therapy (SBRT): analysis of predictive factors. Int J Radiat Oncol Biol Phys 2012, 84:e343-e349.
47. Siddiqui F., Raben D., Lu J.J., et al. Emerging applications of stereotactic body radiation therapy for head and neck cancer. Expert Rev Anticancer Ther 2011, 11:1429-1436.
48. Cengiz M., Ozyigit G., Yazici G., et al. Salvage reirradiaton with stereotactic body radiotherapy for locally recurrent head-and-neck tumors. Int J Radiat Oncol Biol Phys 2011, 81:104-109.
49. Kunos C., von Gruenigen V., Waggoner S., et al. Cyberknife radiosurgery for squamous cell carcinoma of vulva after prior pelvic radiation therapy. Technol Cancer Res Treat 2008, 7:375-380.
50. Kunos C., Chen W., DeBernardo R., et al. Stereotactic body radiosurgery for pelvic relapse of gynecologic malignancies. Technol Cancer Res Treat 2009, 8:393-400.
51. Mayr N.A., Huang Z., Sohn J.W., et al. Emerging application of stereotactic body radiation therapy for gynecologic malignancies. Expert Rev Anticancer Ther 2011, 11:1069-1075.
52. Ishiyama H., Teh B.S., Lo S.S., et al. Stereotactic body radiation therapy for prostate cancer. Future Oncol 2011, 7:1077-1086.
53. Boike T.P., Lotan Y., Cho L.C., et al. Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. J Clin Oncol 2011, 29:2020-2026.
54. King C.R., Brooks J.D., Gill H., Presti J.C. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys 2012, 82:877-882.
55. Kunos C.A., Debernardo R., Radivoyevitch T., et al. Hematological toxicity after robotic stereotactic body radiosurgery for treatment of metastatic gynecologic malignancies. Int J Radiat Oncol Biol Phys 2012, 84:e35-e41.
56. Lo S.S., Fakiris A.J., Wang J.Z., Mayr N.A. In regard to Hoppe et al. (Int J Radiat Oncol Biol Phys 2008;72:1283-1286). Int J Radiat Oncol Biol Phys 2009, 74:977. author reply 8.
57. Lo S.S., Sahgal A., Wang J.Z., et al. Stereotactic body radiation therapy for spinal metastases. Discov Med 2010, 9:289-296.
58. Rusthoven K.E., Kavanagh B.D., Burri S.H., et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol 2009, 27:1579-1584.
59. Chang E.L., Shiu A.S., Mendel E., et al. Phase I/II study of stereotactic body radiotherapy for spinal metastasis and its pattern of failure. J Neurosurg Spine 2007, 7:151-160.
60. Amdur R.J., Bennett J., Olivier K., et al. A prospective, phase II study demonstrating the potential value and limitation of radiosurgery for spine metastases. Am J Clin Oncol 2009, 32:515-520.
61. Garg A.K., Shiu A.S., Yang J., et al. Phase 1/2 trial of single-session stereotactic body radiotherapy for previously unirradiated spinal metastases. Cancer 2012, 118:5069-5077.
62. Henderson M., McGarry R., Yiannoutsos C., et al. Baseline pulmonary function as a predictor for survival and decline in pulmonary function over time in patients undergoing stereotactic body radiotherapy for the treatment of stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2008, 72:404-409.
63. Stephans K.L., Djemil T., Reddy C.A., et al. Comprehensive analysis of pulmonary function test (PFT) changes after stereotactic body radiotherapy (SBRT) for stage I lung cancer in medically inoperable patients. J Thorac Oncol 2009, 4:838-844.
64. Bishawi M., Kim B., Moore W.H., Bilfinger T.V. Pulmonary function testing after stereotactic body radiotherapy to the lung. Int J Radiat Oncol Biol Phys 2012, 82:e107-110.
65. Baumann P., Nyman J., Hoyer M., et al. Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer - a first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study. Radiother Oncol 2008, 88:359-367.
66. Yang J., Fowler J.F., Lamond J.P., Lanciano R., Feng J., Brady L.W. Red shell: defining a high-risk zone of normal tissue damage in stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2010, 77:903-909.
67. Park C., Papiez L., Zhang S., Story M., Timmerman R.D. Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys 2008, 70:847-852.
68. Wang J.Z., Huang Z., Lo S.S., Yuh W.T., Mayr N.A. A generalized linear-quadratic model for radiosurgery, stereotactic body radiation therapy, and high-dose rate brachytherapy. Sci Transl Med 2010, 2:39ra48.